Distribution of mucosal PD-1 expressing T cells in patients with colitis of different etiologies

Roosenboom, Britt; Horje, Carmen S. Horjus Talabur; Smids, Carolijn; Leeuwis, Jan Willem; Koolwijk, Elly van; Groenen, Marcel; Wahab, Peter J.; Lochem, Ellen G. van

doi:10.1080/00365521.2021.1906316

Cited by 8 publications

(11 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nakazawa et al [30] reported that intestinal epithelial cells from patients with IBD but not normal controls expressed PD-1 and PD-L1 protein on their surface. Recently Roosenboom et al [31] described PD-1+ and PD-L1+ lymphocytes in the colonic mucosa of UC patients comparing to normal control and -interestingly -to CD group. The observations of PD-1 expression in UC and PD-1 inhibitor-associated colitis have also shown contrary results suggesting that the role of PD-1 pathway in IBD-pathogenesis could be more complex, than it has been expected [31,32].…”

Section: Colon (Uc)mentioning

confidence: 99%

“…Recently Roosenboom et al [31] described PD-1+ and PD-L1+ lymphocytes in the colonic mucosa of UC patients comparing to normal control and -interestingly -to CD group. The observations of PD-1 expression in UC and PD-1 inhibitor-associated colitis have also shown contrary results suggesting that the role of PD-1 pathway in IBD-pathogenesis could be more complex, than it has been expected [31,32]. Chulkina et al [33] made an attempt to summarize these observations, concluding that the relative con-…”

Section: Colon (Uc)mentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of spatial PD1 and PD-L1 expression in inflammatory bowel disease samples – a pilot study

Szczepaniak¹,

Paskal²,

Kusmierczyk³

et al. 2022

pjp

View full text Add to dashboard Cite

Alterations of PD1/PD-L1 pathway may be associated with an excessive inflammatory response in the intestinal wall in inflammatory bowel diseases (IBD). To evaluate the expression of PD-1 and PD-L1 in 4 compartments of intestinal wall (mucosa, submucosa, muscularis propria and lymphatic follicles), high-resolution immunohistochemically stained slides were obtained from formalin-fixed paraffin-embedded samples of 10 Crohn's disease (CD), 9 ulcerative colitis (UC) and 10 unaffected individuals cases. The levels of expression were quantified using the Qu-Path software. PD-1 was detected in lymphatic follicles in affected and unaffected tissue samples and in inflammatory infiltration in IBD. There was no difference between groups neither in PD-1 overall expression nor in individual compartments, with the exception of the mucosal expression. It was higher in the mucosa of CD patients comparing to controls, however this difference was marginal (p = 0.0461). PD-L1 was expressed in endothelium and mesenteric nervous plexi, consistently in each group. There were no significant differences in PD-L1 immunoreactivity in context of histologic compartment nor clinical diagnosis. The results suggest that PD-1 and PD-L1 expression in intestinal tissue is heterogeneous in the analysed groups, thus it may be dependent on individual characteristics.

show abstract

Section: Colon (Uc)mentioning

confidence: 99%

Section: Colon (Uc)mentioning

confidence: 99%

Evaluation of spatial PD1 and PD-L1 expression in inflammatory bowel disease samples – a pilot study

Szczepaniak¹,

Paskal²,

Kusmierczyk³

et al. 2022

pjp

View full text Add to dashboard Cite

show abstract

“…9 Another study demonstrated that the proportion of PD-1 + T cells was higher in UC than in CD, infectious colitis, ICI induced colitis, and healthy controls. 10 However, these studies did not compare PD-1 + cells across T-cell subsets, nor did they focus primarily on differentiating IBD from other in ammatory diseases. Also, because these studies used conventional IHC, quantitative analysis of PD-1 + cells could not be performed, and ratio of PD-1 + cell was compared.…”

Section: Discussionmentioning

confidence: 99%

“…27 In this study, PD-1 expression in the ileum and colon was similar, which was similar with the study mentioned before. 10 Therefore, the confounding effect concerning the location of biopsy specimens is assumed to be insigni cant.…”

Section: Discussionmentioning

confidence: 99%

PD-1-positive cells contribute to the diagnosis of inflammatory bowel disease and can aid in predicting response to vedolizumab

Kim,

Jo,

Kim

et al. 2023

Preprint

View full text Add to dashboard Cite

Differentiating inflammatory bowel disease (IBD) from other inflammatory diseases is often challenging. Programmed cell death protein-1 (PD-1) is expressed in T cells and is an indicator of their exhaustion. The role of PD-1 expression in diagnosing IBD and predicting the response of biologic agents remains inconclusive. In this study, endoscopic biopsy samples of 19 patients diagnosed with IBD, intestinal tuberculosis, and intestinal Behcet’s disease were analyzed using multiplexed immunohistochemistry. Additionally, a separate "vedolizumab (VDZ) cohort" established in ulcerative colitis patients who underwent endoscopic biopsy before VDZ administration was analyzed to predict response to VDZ. In the immunohistochemistry analysis, the cell density of T cell subsets, including PD-1 + cells, was investigated and compared between IBD and other inflammatory diseases (OID). Cell densities of PD-1 + cells (p = 0.028), PD-1 + helper T cells (p = 0.008), and PD-1 + regulatory T cells (p = 0.024) were higher in IBD compared with OID. In the VDZ cohort, patients with a 14-week steroid-free clinical response had higher levels of PD-1 + cells (p = 0.026), PD-1 + helper T cells (p = 0.026), and PD-1 + regulatory T cells (p = 0.041) than the no response group. PD-1 + immune cells may contribute to the diagnosis of IBD and could be used to predict response to VDZ in ulcerative colitis patients.

show abstract

“…Its ligand binding can participate in the occurrence of intestinal mucositis by activating initial T lymphocytes, inhibiting activated effector T lymphocytes, and regulating the secretion of cytokines[ 43 ]. Studies have shown that in patients with UC, the expression level of PD-1 in inflammatory sites is significantly increased, while intestinal mucositis is alleviated when the PD-1 pathway is blocked[ 44 ]. CD38 is expressed on intestinal inflammatory cells, which has been reported to promote intestinal inflammation.…”

Section: Discussionmentioning

confidence: 99%

Curcumin alleviates experimental colitis via a potential mechanism involving memory B cells and Bcl-6-Syk-BLNK signaling

Sun¹,

Wu²,

Huang³

et al. 2022

World J Gastroenterol

View full text Add to dashboard Cite

BACKGROUND Immune dysfunction is the crucial cause in the pathogenesis of inflammatory bowel disease (IBD), which is mainly related to lymphocytes (T or B cells, incl-uding memory B cells), mast cells, activated neutrophils, and macrophages. As the precursor of B cells, the activation of memory B cells can trigger and differentiate B cells to produce a giant variety of inducible B cells and tolerant B cells, whose dysfunction can easily lead to autoimmune diseases, including IBD. AIM To investigate whether or not curcumin (Cur) can alleviate experimental colitis by regulating memory B cells and Bcl-6-Syk-BLNK signaling. METHODS Colitis was induced in mice with a dextran sulphate sodium (DSS) solution in drinking water. Colitis mice were given Cur (100 mg/kg/d) orally for 14 con-secutive days. The colonic weight, colonic length, intestinal weight index, occult blood scores, and histological scores of mice were examined to evaluate the curative effect. The levels of memory B cells in peripheral blood of mice were measured by flow cytometry, and IL-1β, IL-6, IL-10, IL-7A, and TNF-α expression in colonic tissue homogenates were analyzed by enzyme-linked immunosorbent assay. Western blot was used to measure the expression of Bcl-6, BLNK, Syk, and other signaling pathway related proteins. RESULTS After Cur treatment for 14 d, the body weight, colonic weight, colonic length, colonic weight index, and colonic pathological injury of mice with colitis were ameliorated. The secretion of IL-1β, IL-6, TNF-α, and IL-7A was statistically decreased, while the IL-35 and IL-10 levels were considerably increased. Activation of memory B cell subsets in colitis mice was confirmed by a remarkable reduction in the expression of IgM, IgG, IgA, FCRL5, CD103, FasL, PD-1, CD38, and CXCR3 on the surface of CD19 + CD27 + B cells, while the number of CD19 + CD27 + IL-10 + and CD19 + CD27 + Tim-3 + B cells increased significantly. In addition, Cur significantly inhibited the protein levels of Syk, p-Syk, Bcl-6, and CIN85, and increased BLNK and p-BLNK expression in colitis mice. CONCLUSION Cur could effectively alleviate DSS-induced colitis in mice by regulating memory B cells and the Bcl-6-Syk-BLNK signaling pathway.

show abstract

Distribution of mucosal PD-1 expressing T cells in patients with colitis of different etiologies

Cited by 8 publications

References 42 publications

Evaluation of spatial PD1 and PD-L1 expression in inflammatory bowel disease samples – a pilot study

Evaluation of spatial PD1 and PD-L1 expression in inflammatory bowel disease samples – a pilot study

PD-1-positive cells contribute to the diagnosis of inflammatory bowel disease and can aid in predicting response to vedolizumab

Curcumin alleviates experimental colitis via a potential mechanism involving memory B cells and Bcl-6-Syk-BLNK signaling

Contact Info

Product

Resources

About